Giulia Gioiello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giulia Gioiello has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Giulio Mengozzi
Department of Medical Sciences, University of Torino, 10126 Torino, Italy
5 shared publications - Aurora Cermelli
Aging Brain and Memory Clinic, Department of Neuroscience “Rita Levi Montalcini”, University of Torino, 10126 Turin, Italy
2 shared publications - Chiara Lombardo
Center for Cognitive Disorders and Dementias (CDCD), Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, 10126 Turin, Italy
2 shared publications - Fausto Roveta
Department of Neuroscience “Rita Levi‐Montalcini” University of Turin Turin Italy
2 shared publications - Selene Limoncelli
Clinical Biochemistry Laboratory, Città della Salute e della Scienza, 10126 Torino, Italy
2 shared publications - Silvia Boschi
Aging Brain and Memory Clinic, Department of Neuroscience “Rita Levi Montalcini”, University of Torino, 10126 Turin, Italy
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by MDPI AG in Laboratories
- Vol. 3 (3) , 20
Organizational Impact of Reflex IgM Testing for Enzymatic Creatinine Interference: A Real-World Study
Introduction: Immunoglobulin M (IgM) paraproteins may interfere with enzymatic creatinine assays, potentially affecting renal function assessment. Reflex IgM testing has been proposed to detect such interference, but its impact on laboratory workflow remains insufficiently characterized. Material and Methods: This retrospective observational study combined two complementary datasets: (1) a clinical cohort of patients evaluated for suspected IgM-related interference over a 7-month period, and (2) a two-month and half representative operational analysis assessing testing volume and turnaround time (TAT) in a high-throughput clinical laboratory. An automated LIS rule triggered IgM testing when creatinine was ≥177 μmol/L. Samples with IgM ≥ 2.5 g/L underwent polyethylene glycol (PEG) precipitation to evaluate potential interference. Test volume and TAT were compared between creatinine-only and reflex workflows. Results: During the 2.5-month operational analysis, 102,849 creatinine measurements were performed, of which 7740 (7.5%) triggered reflex IgM testing, generating 11,091 IgM determinations, 56.5% of which were reflex-driven. During the full seven-month clinical observation period, clinically relevant IgM-related interference was confirmed in 8 patients. Reflex workflows were associated with increased TAT compared with creatinine-only testing. Conclusions: Universal reflex IgM testing improves detection of rare analytical interference but generates substantial workload and increases TAT. During the 2.5-month operational analysis period, only 2 of 7740 reflex-triggered samples (0.026%) resulted in confirmed clinically relevant interference. A selective, risk-based strategy may therefore represent a more efficient and sustainable approach to routine laboratory practice.
- 3 September 2026
- Published by MDPI AG in Laboratories
- Vol. 3 (3) , 20
Open AccessOrganizational Impact of Reflex IgM Testing for Enzymatic Creatinine Interference: A Real-World Study
Introduction: Immunoglobulin M (IgM) paraproteins may interfere with enzymatic creatinine assays, potentially affecting renal function assessment. Reflex IgM testing has been proposed to detect such interference, but its impact on laboratory workflow remains insufficiently characterized. Material and Methods: This retrospective observational study combined two complementary datasets: (1) a clinical cohort of patients evaluated for suspected IgM-related interference over a 7-month period, and (2) a two-month and half representative operational analysis assessing testing volume and turnaround time (TAT) in a high-throughput clinical laboratory. An automated LIS rule triggered IgM testing when creatinine was ≥177 μmol/L. Samples with IgM ≥ 2.5 g/L underwent polyethylene glycol (PEG) precipitation to evaluate potential interference. Test volume and TAT were compared between creatinine-only and reflex workflows. Results: During the 2.5-month operational analysis, 102,849 creatinine measurements were performed, of which 7740 (7.5%) triggered reflex IgM testing, generating 11,091 IgM determinations, 56.5% of which were reflex-driven. During the full seven-month clinical observation period, clinically relevant IgM-related interference was confirmed in 8 patients. Reflex workflows were associated with increased TAT compared with creatinine-only testing. Conclusions: Universal reflex IgM testing improves detection of rare analytical interference but generates substantial workload and increases TAT. During the 2.5-month operational analysis period, only 2 of 7740 reflex-triggered samples (0.026%) resulted in confirmed clinically relevant interference. A selective, risk-based strategy may therefore represent a more efficient and sustainable approach to routine laboratory practice.
- Open Access
Good Manufacturing Practice-Derived Human Liver Stem Cell Extracellular Vesicles Attenuate Liver Fibrosis In Vivo
Human liver stem cells (HLSCs) are a mesenchymal stromal cell (MSC)-like population isolated from adult liver biopsies. HLSCs share key characteristics with MSCs, including phenotype and differentiation capabilities. Previous studies have demonstrated that HLSCs promote regeneration in different experimental models of acute and chronic tissue injury and that HLSC-derived extracellular vesicles (HLSC-EVs) recapitulate the therapeutic effects of the cells of origin. This study aimed to determine whether HLSC-EVs, obtained and characterized under good manufacturing practice (GMP) conditions, can influence the progression of liver fibrosis in vivo. The EV production process was carried out under GMP conditions to generate batches of HLSC-EVs by tangential flow filtration. To assess their therapeutic potential, an in vivo model of hepatic fibrosis was established through administration of thioacetamide (TAA). In TAA-treated mice, EV administrations attenuated fibrosis progression. Molecular analyses showed a significant reduction in the expression levels of key pro-fibrotic genes. At the functional level, EV administration resulted in a significant reduction in plasma alanine aminotransferase levels and an increase in albumin levels, indicating improved liver function. These data indicate that HLSC-EVs, produced under GMP conditions, display antifibrotic effects in a chronic liver disease model, leading to improved liver function and histology.
Open AccessGood Manufacturing Practice-Derived Human Liver Stem Cell Extracellular Vesicles Attenuate Liver Fibrosis In Vivo
Human liver stem cells (HLSCs) are a mesenchymal stromal cell (MSC)-like population isolated from adult liver biopsies. HLSCs share key characteristics with MSCs, including phenotype and differentiation capabilities. Previous studies have demonstrated that HLSCs promote regeneration in different experimental models of acute and chronic tissue injury and that HLSC-derived extracellular vesicles (HLSC-EVs) recapitulate the therapeutic effects of the cells of origin. This study aimed to determine whether HLSC-EVs, obtained and characterized under good manufacturing practice (GMP) conditions, can influence the progression of liver fibrosis in vivo. The EV production process was carried out under GMP conditions to generate batches of HLSC-EVs by tangential flow filtration. To assess their therapeutic potential, an in vivo model of hepatic fibrosis was established through administration of thioacetamide (TAA). In TAA-treated mice, EV administrations attenuated fibrosis progression. Molecular analyses showed a significant reduction in the expression levels of key pro-fibrotic genes. At the functional level, EV administration resulted in a significant reduction in plasma alanine aminotransferase levels and an increase in albumin levels, indicating improved liver function. These data indicate that HLSC-EVs, produced under GMP conditions, display antifibrotic effects in a chronic liver disease model, leading to improved liver function and histology.
- Open Access
- 24 August 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (9) , 911
Comparison of Simoa and Lumipulse Neurofilament Light Chain Measurements in Alzheimer’s Cerebrospinal Fluid: Preliminary Findings
Background: Neurofilament light chain (NfL) is a promising biomarker of neuroaxonal injury, increasingly used to monitor neurodegeneration in Alzheimer’s disease (AD). Multiple analytical platforms are available for NfL quantification in cerebrospinal fluid (CSF), but data on cross-platform consistency remain limited. Objective: This pilot study aimed to provide CSF NfL concentrations measured using Simoa and Lumipulse immunoassays in patients with biologically confirmed AD. Methods: Twenty-eight patients with cognitive impairment fulfilling the biological criteria for AD were enrolled. CSF NfL levels were measured using both Simoa and Lumipulse immunoassays. Statistical analyses assessed intra-individual agreement, correlation between platforms, and associations with cognitive status. Results: NfL concentrations measured with Simoa and Lumipulse showed a strong positive correlation between platforms (Spearman’s ρ = 0.965, p < 0.001), demonstrating excellent analytical concordance. Conclusions: In this pilot study, Simoa and Lumipulse yielded strongly correlated CSF NfL measurements, providing initial evidence of cross-platform consistency. However, these findings require confirmation in larger and diverse cohorts before definitive validation.
- 24 August 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (9) , 911
Open AccessComparison of Simoa and Lumipulse Neurofilament Light Chain Measurements in Alzheimer’s Cerebrospinal Fluid: Preliminary Findings
Background: Neurofilament light chain (NfL) is a promising biomarker of neuroaxonal injury, increasingly used to monitor neurodegeneration in Alzheimer’s disease (AD). Multiple analytical platforms are available for NfL quantification in cerebrospinal fluid (CSF), but data on cross-platform consistency remain limited. Objective: This pilot study aimed to provide CSF NfL concentrations measured using Simoa and Lumipulse immunoassays in patients with biologically confirmed AD. Methods: Twenty-eight patients with cognitive impairment fulfilling the biological criteria for AD were enrolled. CSF NfL levels were measured using both Simoa and Lumipulse immunoassays. Statistical analyses assessed intra-individual agreement, correlation between platforms, and associations with cognitive status. Results: NfL concentrations measured with Simoa and Lumipulse showed a strong positive correlation between platforms (Spearman’s ρ = 0.965, p < 0.001), demonstrating excellent analytical concordance. Conclusions: In this pilot study, Simoa and Lumipulse yielded strongly correlated CSF NfL measurements, providing initial evidence of cross-platform consistency. However, these findings require confirmation in larger and diverse cohorts before definitive validation.
- 26 January 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1_suppl)
Diagnostic performance of plasma biomarkers for Alzheimer's disease using a fully automated platform: A real-world clinical study
This study evaluated the diagnostic performance of plasma biomarkers for Alzheimer's disease (AD) using an automated platform. In a cohort of 74 consecutive patients, plasma p-Tau181 levels were significantly higher in AD compared to non-AD groups and showed correlation with cerebrospinal fluid biomarkers. Plasma p-Tau181 demonstrated high diagnostic accuracy for AD, with an area under the curve of 0.854. The findings suggest that plasma biomarkers, particularly p-Tau181, could improve the accessibility and efficiency of AD diagnostics in clinical settings, offering a less invasive and cost-effective alternative to traditional methods.
- 26 January 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1_suppl)
Diagnostic performance of plasma biomarkers for Alzheimer's disease using a fully automated platform: A real-world clinical study
This study evaluated the diagnostic performance of plasma biomarkers for Alzheimer's disease (AD) using an automated platform. In a cohort of 74 consecutive patients, plasma p-Tau181 levels were significantly higher in AD compared to non-AD groups and showed correlation with cerebrospinal fluid biomarkers. Plasma p-Tau181 demonstrated high diagnostic accuracy for AD, with an area under the curve of 0.854. The findings suggest that plasma biomarkers, particularly p-Tau181, could improve the accessibility and efficiency of AD diagnostics in clinical settings, offering a less invasive and cost-effective alternative to traditional methods.
- Open Access
- 2 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8453
Diagnostic Accuracy of Aldosterone and Renin Measurement by Chemiluminescence for Screening of Patients with Primary Aldosteronism
Primary aldosteronism (PA) is the most common cause of endocrine arterial hypertension, and the suggested screening test for case detection is the aldosterone-to-renin ratio (ARR) or aldosterone-to-direct renin ratio (ADRR) based on radio-immunoassay (RIA) and chemiluminescence assay (CLIA), respectively. The objective of our study was to evaluate the reliability of CLIA for aldosterone and renin measurement and the diagnostic performance of ADRR. A prospective cohort of 1110 patients referred to a single laboratory medicine center underwent measurement of aldosterone and direct renin concentration (DRC) by CLIA and measurement of aldosterone and plasma renin activity (PRA) by RIA. Of 1110 patients, 640 obtained a final diagnosis of hypertension, and 90 of these patients were diagnosed with PA. Overall, between-method correlation was highly significant for aldosterone concentrations (R = 0.945, p < 0.001) and less strong but significant for DRC/PRA (R = 0.422, p < 0.001). Among hypertensive patients, in PA cases, the areas under the receiver operator characteristics (ROC) curves were 0.928 (95% confidence interval 0.904–0.954) for ADRR and 0.943 (95% confidence interval 0.920–0.966) for ARR and were comparable and not significantly different. The highest accuracy was obtained with an ADRR cut-off of 25 (ng/L)/(mIU/L), displaying a sensitivity of 91% and a specificity of 85%. The chemiluminescence assay for aldosterone and DRC is a reliable method for PA diagnosis compared to the classical RIA method.
- 2 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8453
Open AccessDiagnostic Accuracy of Aldosterone and Renin Measurement by Chemiluminescence for Screening of Patients with Primary Aldosteronism
Primary aldosteronism (PA) is the most common cause of endocrine arterial hypertension, and the suggested screening test for case detection is the aldosterone-to-renin ratio (ARR) or aldosterone-to-direct renin ratio (ADRR) based on radio-immunoassay (RIA) and chemiluminescence assay (CLIA), respectively. The objective of our study was to evaluate the reliability of CLIA for aldosterone and renin measurement and the diagnostic performance of ADRR. A prospective cohort of 1110 patients referred to a single laboratory medicine center underwent measurement of aldosterone and direct renin concentration (DRC) by CLIA and measurement of aldosterone and plasma renin activity (PRA) by RIA. Of 1110 patients, 640 obtained a final diagnosis of hypertension, and 90 of these patients were diagnosed with PA. Overall, between-method correlation was highly significant for aldosterone concentrations (R = 0.945, p < 0.001) and less strong but significant for DRC/PRA (R = 0.422, p < 0.001). Among hypertensive patients, in PA cases, the areas under the receiver operator characteristics (ROC) curves were 0.928 (95% confidence interval 0.904–0.954) for ADRR and 0.943 (95% confidence interval 0.920–0.966) for ARR and were comparable and not significantly different. The highest accuracy was obtained with an ADRR cut-off of 25 (ng/L)/(mIU/L), displaying a sensitivity of 91% and a specificity of 85%. The chemiluminescence assay for aldosterone and DRC is a reliable method for PA diagnosis compared to the classical RIA method.